PMID- 37127827
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 11
DP  - 2023 Sep
TI  - Feasibility study of expressing epcam + /vimentin + CTC in prostate cancer 
      diagnosis.
PG  - 8699-8709
LID - 10.1007/s00432-023-04819-7 [doi]
AB  - PURPOSE: Prostate cancer (PCa) is one of the most common malignancies in men and 
      one of the leading causes of cancer-related deaths; circulating tumor cells (CTC) 
      are malignant cells that have broken off from original tumor or metastatic sites 
      and extravasated into the blood vessels either naturally or maybe as a 
      consequence of surgical procedures. This study aims to explore the feasibility of 
      liquid biopsy technique to diagnose prostate cancer. METHOD: We constructed an 
      assay platform integrating magnetic separation and fluorescence in situ 
      hybridization (FISH) to effectively capture prostate cancer CTCs and evaluate the 
      distribution between healthy volunteers and prostate cancer patients, 
      respectively. RESULTS: There was a significant difference in the number of CTCs 
      between the healthy population and prostate cancer patients (P < 0.001). The 
      results of the study showed that the CTCs capture identification system has good 
      sensitivity and specificity in identifying prostate cancer patients. CONCLUSION: 
      The CTCs test allows us to accurately identify patients who are at high risk for 
      prostate cancer, allowing for early intervention and treating patients 
      effectively.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Chen, Junyong
AU  - Chen J
AD  - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with 
      Jinan University), 79 Kangning Rd., Zhuhai, 519000, China.
FAU - Xie, Tao
AU  - Xie T
AD  - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with 
      Jinan University), 79 Kangning Rd., Zhuhai, 519000, China.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Pathology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated 
      with Jinan University), Zhuhai, 519000, China.
FAU - Lin, Xuehua
AU  - Lin X
AD  - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with 
      Jinan University), 79 Kangning Rd., Zhuhai, 519000, China.
FAU - Huang, Long
AU  - Huang L
AD  - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with 
      Jinan University), 79 Kangning Rd., Zhuhai, 519000, China. 
      huangxinlongwwf@126.com.
FAU - Su, Shiya
AU  - Su S
AD  - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with 
      Jinan University), 79 Kangning Rd., Zhuhai, 519000, China. 13727075317@163.com.
FAU - Deng, Jian
AU  - Deng J
AD  - Department of Urology, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with 
      Jinan University), 79 Kangning Rd., Zhuhai, 519000, China. 
      zhdengjian2008@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230501
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Epithelial Cell Adhesion Molecule)
RN  - 0 (Vimentin)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - Male
MH  - Epithelial Cell Adhesion Molecule/genetics
MH  - Feasibility Studies
MH  - Vimentin
MH  - In Situ Hybridization, Fluorescence
MH  - Biomarkers, Tumor/genetics
MH  - *Prostatic Neoplasms/diagnosis/genetics
MH  - *Neoplastic Cells, Circulating/pathology
OTO - NOTNLM
OT  - Circulating tumor cell
OT  - Fluorescence in situ hybridization
OT  - Liposome magnetic beads
OT  - Prostate cancer
EDAT- 2023/05/02 00:42
MHDA- 2023/07/31 06:43
CRDT- 2023/05/01 23:28
PHST- 2023/03/07 00:00 [received]
PHST- 2023/04/24 00:00 [accepted]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/05/02 00:42 [pubmed]
PHST- 2023/05/01 23:28 [entrez]
AID - 10.1007/s00432-023-04819-7 [pii]
AID - 10.1007/s00432-023-04819-7 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 Sep;149(11):8699-8709. doi: 
      10.1007/s00432-023-04819-7. Epub 2023 May 1.